DIAGNOSTIC REPORT

Patient Ref. No. 2000011020047

Cert. No. MC-2010

CLIENT CODE : C12345

CLIENT'S NAME AND ADDRESS :
FPSC PRIMECARE DIAGNOSTICS
SHOP NO. 15 GROUND FLOOR, ASIATIC ARCADE POKHARAN, ROAD NO. 1 VARTAK NAGAR,
THANE (W),
THANE 400606
MAHARASHTRA INDIA
8268383520

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
MUMBAI, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax : 022 - 67801212
CIN - U74899PB1995PLC045956

PATIENT NAME : Minnie Mouse PATIENT ID : **ABC12345**

ACCESSION NO : **23456** AGE : 40 Years SEX : Female

DRAWN : 30/05/2022 10:34 RECEIVED : 30/05/2022 14:54 REPORTED : 30/05/2022 17:09

REFERRING DOCTOR : DR. TEJINDER SINGH CLIENT PATIENT ID :

Test Report Status **Final**	Results	Biological Reference Interval	Units

SPECIALISED CHEMISTRY - TUMOR MARKER

CA 15-3, SERUM

CA 15-3	12.00	< or = 34.50	U/mL

METHOD : SANDWICH ELECTROCHEMILUMINESCENCE IMMUNOASSAY

Interpretation(s)
CA 15-3, SERUM-CA 15-3 is a circulating tumor marker, which is useful in monitoring the clinical course of breast cancer patients.Whereas, elevated levels are only present in a small percentage of patients with localized disease, two thirds of the cases with metastatic disease will have significantly elevated levels.

CA 15-3, which can monitor response to therapy and can indicate disease status, is a valuable tool in the management of patients with metastases. It can be used for serial measurements to monitor both the course of disease and response to therapy because of the direct correlation of changing levels of CA 15-3 with clinical status.In patients with known metastases, a reduction in levels of this marker indicates a good response to treatment, while increasing levels indicate resistance to therapy and progressive disease and justify further clinical evaluation and regular monitoring.

It has also recently been shown that an elevation of CA 15-3 levels above the upper limit of normal in patients with no clinical evidence of disease is an early indicator of recurrence. An elevated serum CA 15-3 level in Stage II or III breast cancer patients in remission provided a positive predictive value of 83.3% for recurrent disease, with an average lead-time of 5.3 months before recurrence was clinically established.

The concentration of CA 15-3 in a given specimen, as determined by assays from different manufacturers, can vary due to differences in assay methods and reagent specificity. Values obtained with different assay method cannot be used interchangeably.

Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Patients routinely exposed to animals or to animal serum products can be prone to this interference and anomalous values may be observed.

****End Of Report****

Please visit www.srlworld.com for related Test Information for this accession

Dr. Kshama P, MD
Biochemist

Scan to View Details

Scan to View Report

DIAGNOSTIC REPORT

Patient Ref. No. 2000011020047

Cert. No. MC-2010

CLIENT CODE : C12345

CLIENT'S NAME AND ADDRESS :
FPSC PRIMECARE DIAGNOSTICS
SHOP NO. 15 GROUND FLOOR, ASIATIC ARCADE POKHARAN, ROAD NO. 1 VARTAK NAGAR,
THANE (W),
THANE 400606
MAHARASHTRA INDIA
8268383520

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
MUMBAI, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax : 022 - 67801212
CIN - U74899PB1995PLC045956

PATIENT NAME : Minnie Mouse PATIENT ID : **ABC12345**

ACCESSION NO : **23456** AGE : 40 Years SEX : Female

DRAWN : 30/05/2022 10:34 RECEIVED : 30/05/2022 14:54 REPORTED : 30/05/2022 17:09

REFERRING DOCTOR : DR. TEJINDER SINGH CLIENT PATIENT ID :

Test Report Status **Final**	Results	Biological Reference Interval	Units

CONDITIONS OF LABORATORY TESTING & REPORTING

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
2. All Tests are performed and reported as per the turnaround time stated in the SRL Directory of services (DOS).
3. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
4. A requested test might not be performed if:
   a. Specimen received is insufficient or inappropriate specimen quality is unsatisfactory
   b. Incorrect specimen type
   c. Request for testing is withdrawn by the ordering doctor or patient
   d. There is a discrepancy between the label on the specimen container and the name on the test requisition form
5. The results of a laboratory test are dependent on the quality of the sample as well as the assay technology.
6. Result delays could be because of uncontrolled circumstances. e.g. assay run failure.
7. Tests parameters marked by asterisks are excluded from the "scope" of NABL accredited tests. (If laboratory is accredited).
8. Laboratory results should be correlated with clinical information to determine Final diagnosis.
9. Test results are not valid for Medico- legal purposes.
10. In case of queries or unexpected test results please call at SRL customer care (91115 91115). Post proper investigation repeat analysis may be carried out.

SRL Limited
Fortis Hospital, Sector 62, Phase VIII,
Mohali 160062

Scan to View Details

Scan to View Report